small - 医索

找到约 68 条结果

Subcutaneous amivantamab vs intravenous amivantamabboth in combination with lazertinib, in refractoryEGFR-mutated,advanced non-small cell lung cancer

医客学院 - 会议报告集

Safety and efficacy of osimertinib plus consolidativestereotactic ablative radiation(SABR) inadvanced EGFR mutant non-small cell lungcancer(NSCLC)results from a multi-center Phase ltrial

医客学院 - 会议报告集

NRG-LU002Randomized Phase lllll Trial Of MaintenanceSystemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy For Limited Metastatic Non-Small Cell Lung Cancer

医客学院 - 会议报告集

Molecular residual disease analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage lB-lllA non-small cell lung cancer

医客学院 - 会议报告集

Managing Expectations WithAntibody-Drug Conjugates in Non-Small Cell Lung Cancer

医客学院 - 会议报告集

Lorlatinib vs Crizotinib in Treatment-NaivePatients With Advanced ALK Non-SmallCell Lung Cancer 5-Year Progression-FreeSurvival and Safety From the CRoWN Study

医客学院 - 会议报告集

Lorlatinib in TKl naive, advanced RoS1-positivenon-small cell lung cancer a multicenter, open-label, single-arm, phase 2 trial

医客学院 - 会议报告集

Ivonescimab combined with chemotherapy in patientswith EGFR-mutant non-squamous non-small cell lungcancer who progressed on EGFR-TKls treatment arandomized, double-blind, multi-center, phase 3 trial(HARM

医客学院 - 会议报告集

EFFICACY AND SAFETY OF TALETRECTINIB INPATIENTS WITH ADVANCED OR METASTATICROS1 NON-SMALL CELL LUNG CANCER THEPHASE 2 TRUST-I STUDY

医客学院 - 会议报告集

Can We Enhance the Benefit ofImmunotherapy in Non-Small CelLung Cancer

医客学院 - 会议报告集

首页
上一页
1
2
3
4
5
6
7
下一页
尾页

今日实时热搜